Agendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer

IRVINE, Calif. & AMSTERDAM & MÖNCHENGLADBACH, Germany--(BUSINESS WIRE)--Agendia, Inc., a leader in gene expression profiling for early-stage breast cancer, today announced the first patient has been enrolled in the PROOFS Registry trial. In partnership with the West German Study Group (WSG), the study aims to determine whether premenopausal women with early HR+ breast cancer, originally defined as clinically high-risk and classified as MammaPrint Low Risk, can avoid chemotherapy, and maintain s